UCB
A biopharmaceutical company focused on severe diseases in neurology and immunology.
UCB | BR
Overview
Corporate Details
- ISIN(s):
- BE0002730118 (+5 more)
- LEI:
- 2138008J191VLSGY5A09
- Country:
- Belgium
- Address:
- ALLÉE DE LA RECHERCHE 60, 1070 ANDERLECHT
- Website:
- https://www.ucb.com/
- Sector:
- Manufacturing
Description
UCB is a global biopharmaceutical company that focuses on creating solutions for people living with severe diseases, primarily in the fields of neurology and immunology. The company's core activities include the research, development, and commercialization of pharmaceutical and biotechnology products. Guided by a patient-centric and science-driven approach, UCB is committed to innovation and sustainability. Through its UCB Ventures arm, it invests in pioneering technologies and companies with the potential to transform patient care. The company also offers personalized support services to patients and healthcare professionals during their treatment journey with a UCB medicine.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-10-09 20:00 |
091025 EN Transparency notification FMR LLC.pdf
|
English | 349.1 KB | ||
| 2025-10-09 20:00 |
091025 FR Notification de transparence FMR LLC.pdf
|
French | 304.7 KB | ||
| 2025-10-09 20:00 |
091025 NL Transparantieverklaring FMR LLC.pdf
|
Dutch | 304.9 KB | ||
| 2025-08-12 20:00 |
EN PR.pdf
|
English | 307.0 KB | ||
| 2025-08-12 20:00 |
FR PR.pdf
|
French | 294.4 KB | ||
| 2025-08-12 20:00 |
NL PR.pdf
|
Dutch | 289.3 KB | ||
| 2025-07-31 07:00 |
UCB PR HY 2025 ENG.pdf
|
English | 615.4 KB | ||
| 2025-07-31 07:00 |
UCB PR HY 2025 FR.pdf
|
French | 590.2 KB | ||
| 2025-07-31 07:00 |
UCB PR HY 2025 NL.pdf
|
Dutch | 983.3 KB | ||
| 2025-07-31 07:00 |
UCB_Half-Year_2025_Report-EN-FINAL.pdf
|
English | 1.5 MB | ||
| 2025-07-31 07:00 |
UCB_Half-Year_2025_Report-FR-FINAL.pdf
|
French | 1.5 MB | ||
| 2025-07-31 07:00 |
UCB_Half-Year_2025_Report-NL-FINAL.pdf
|
Dutch | 1.5 MB | ||
| 2025-07-10 20:00 |
EN FMR 10.07.2025.pdf
|
English | 348.5 KB | ||
| 2025-07-10 20:00 |
FR FMR 10.07.2025.pdf
|
French | 304.0 KB | ||
| 2025-07-10 20:00 |
NL FMR 10.07.2025.pdf
|
Dutch | 304.0 KB |
Automate Your Workflow. Get a real-time feed of all UCB filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for UCB
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for UCB via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-04-28 | Caeymaex Emmanuel | Executive member | Sell | 2,597 | 389,420.15 EUR |
| 2025-04-22 | Peacock Jonathan | Board | Buy | 674 | 93,247.90 EUR |
| 2025-04-01 | Lund- Jürgensen Kirsten | Executive member | Buy | 2,143 | N/A |
| 2025-03-04 | Caeymaex Emmanuel | Executive member | Sell | 7,000 | 1,362,568.51 EUR |
| 2025-03-04 | Caeymaex Emmanuel | Executive member | Buy | 7,000 | 532,630.00 EUR |
| 2025-03-03 | Caeymaex Emmanuel | Executive member | Sell | 4,100 | 769,226.28 EUR |
| 2025-03-03 | Caeymaex Emmanuel | Executive member | Sell | 2,822 | 522,643.25 EUR |
| 2025-03-03 | Caeymaex Emmanuel | Executive member | Buy | 4,100 | 271,338.00 EUR |
| 2025-03-03 | Caeymaex Emmanuel | Executive member | Buy | 2,822 | 198,273.72 EUR |
| 2025-02-28 | Caeymaex Emmanuel | Executive member | Sell | 7,000 | 1,260,465.07 EUR |
Peer Companies
